Total Type 1 Type 2
Author, year Study design No.pts Meanage (yrs) M F Abnormal FE-1 No. (%) No.pts Abnormal FE-1 No. (%) No.pts Abnormal FE-1 No. (%)
    n=2891   n=1757 n=1134 n=921 n=921 n=365 n=1970 n=556
Hardt P et al. [24] Case-control 114 60 67 47 46 (40) 31 17 (55) 83 29 (35)
Rathmann W. et al [31] Case-control 544 63 348 196 165 (30) - - 544 165 (30)
Icks A et al. [29] Case-control 112 37 57 55 51(46) 112 51 (46) - -
Hardt P et al. [36] Case series 1020 50 687 333 413 (40) 323 166 (51) 697 247 (35)
Nunes AC et al. [32] Case-control 42 62 18 24 15 (36) - - 42 15 (36)
Cavalot F et al. [30] Case-control 37 34 16 21 21 (57) 37 21 (57) - -
Yilmaztepe A et al. [33] Case-control 32 47 15 17 10 (31) - - 32 10 (31)
Hahn J et al. [15] Case series 33 40 17 16 15 (45) 33 15 (45) - -
Vesterhus M et al. [28] Case-control 140 21 70 70 26 (19) 140 26 (19) - -
Larger E et al. [26] Case series 667 57 390 277 151 (23) 195 66 (34) 472 85 (18)
Vujasinovic M et al. [27] Case series 150 59 72 78 8 (5) 50 3 (6) 100 5 (5)
Table 1: Characteristics of enrolled trials and prevalence of abnormal (<200 μg/g) fecal elastase 1 (FE-1) levels in diabetic patients